CooperVision sponsors Optometry Giving Sight, gets FDA OK for Avaira toric CLs

Article

The Food and Drug Administration has granted a Special 510(k) clearance for CooperVision's Avaira Toric 2-week silicone hydrogel contact lenses for astigmatism. The lenses are available for select distribution beginning this month.

Pleasanton, CA-The Food and Drug Administration has granted a Special 510(k) clearance for CooperVision's Avaira Toric 2-week silicone hydrogel contact lenses for astigmatism. The lenses are available for select distribution beginning this month.

The company also has made a 2-year commitment to support Optometry Giving Sight as a Platinum Gold Sponsor. The World Council of Optometry, the International Centre created Optometry Giving Sight in 2003 for Eyecare Education and the International Agency for the Prevention of Blindness to mobilize resources from the global optometric community to fund sustainable vision care in underserved areas.

“This is a very significant commitment by our company to an organization that we believe is having a substantial impact on the delivery of sustainable eye care services in underserved communities throughout the world,” CooperVision President John Weber said. “As a global company, we think it makes absolute sense to actively support a global charity, especially one that is doing so much to promote and develop optometry as a respected and recognized profession throughout the world.”

For more articles in this issue of InDispensable, click here.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.